MARKET

INTS

INTS

INTENSITY THERAPEUTICS INC
NASDAQ
2.320
-0.005
-0.22%
After Hours: 2.390 +0.07 +3.02% 16:16 03/14 EDT
OPEN
2.130
PREV CLOSE
2.325
HIGH
2.380
LOW
2.130
VOLUME
9.46K
TURNOVER
--
52 WEEK HIGH
5.78
52 WEEK LOW
1.500
MARKET CAP
35.04M
P/E (TTM)
-1.9591
1D
5D
1M
3M
1Y
5Y
1D
INTENSITY THERAPEUTICS, INC. FORM 10-K FOR THE YEAR ENDED DECEMBER 31, 2024
Press release · 3d ago
Intensity Therapeutics GAAP EPS of -$1.17 in-line
Seeking Alpha · 3d ago
*Intensity Therapeutics Reports 2024 Yr End Fincl Results and Provides Corporate Update
Dow Jones · 3d ago
Press Release: Intensity Therapeutics Reports 2024 Year End Financial Results and Provides Corporate Update
Dow Jones · 3d ago
Weekly Report: what happened at INTS last week (0303-0307)?
Weekly Report · 6d ago
Weekly Report: what happened at INTS last week (0224-0228)?
Weekly Report · 03/03 12:25
Weekly Report: what happened at INTS last week (0217-0221)?
Weekly Report · 02/24 12:25
Weekly Report: what happened at INTS last week (0210-0214)?
Weekly Report · 02/17 12:21
More
About INTS
Intensity Therapeutics, Inc. is a late-stage clinical biotechnology company. The Company is engaged in developing treatments that address both the regional and systemic nature of a patient’s cancer. Its platform creates patented anti-cancer product candidates comprising active anti-cancer agents and amphiphilic molecules. Its lead investigational product candidate, INT230-6, is designed for direct intratumoral injection. Its INT230-6 is primarily comprised of three components: cisplatin, vinblastine sulfate and an amphiphilic molecule (SHAO) which enables the two cytotoxic agents to disperse through a tumor and diffuse into cancer cells following a direct intratumoral injection. Its pipeline consists of Phase III open-label, randomized study testing the superiority of INT230-6 used as monotherapy compared to the standard of care drugs in 2nd and 3rd line treatment for certain soft tissue sarcoma subtypes, and Phase II/III clinical study in metastatic triple negative breast cancer.

Webull offers Intensity Therapeutics Inc stock information, including NASDAQ: INTS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, INTS stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading INTS stock methods without spending real money on the virtual paper trading platform.